LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Начало・Списък с акции・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Затворен

1.14 -7.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.12

Максимум

1.25

Ключови измерители
By Trading Economics
Приходи	418K -5.5M
EPS	-0.18
Марж на печалбата	-6,600
Служители	25
EBITDA	525K -5.7M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+380% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	4.4M 42M
Предишно отваряне	8.46
Предишно затваряне	1.14

Actinium Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.05.2026 г., 23:53 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15.05.2026 г., 22:47 ч. UTC

Горещи акции

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15.05.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15.05.2026 г., 22:00 ч. UTC

Значими двигатели на пазара

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15.05.2026 г., 18:09 ч. UTC

Значими двигатели на пазара

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

17.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17.05.2026 г., 23:36 ч. UTC

Пазарно говорене

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17.05.2026 г., 23:07 ч. UTC

Придобивния, сливания и поглъщания

UOB: Transactions Part of Group's Capital Reallocation Strategy

17.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

UOB: Share Sale Agreements Entered With Singland Properties

17.05.2026 г., 23:05 ч. UTC

Придобивния, сливания и поглъщания

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Fund Stake Acquisition via Internal Resources

17.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Acquire Stake for $389 Million

17.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16.05.2026 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16.05.2026 г., 15:26 ч. UTC

Придобивния, сливания и поглъщания

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15.05.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15.05.2026 г., 21:16 ч. UTC

Пазарно говорене

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 20:19 ч. UTC

Горещи акции

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15.05.2026 г., 19:41 ч. UTC

Придобивния, сливания и поглъщания

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15.05.2026 г., 19:35 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15.05.2026 г., 18:35 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Actinium Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

380% нагоре

12-месечна прогноза

Среден 6 USD 380%

Висок 9 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Actinium Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Actinium Pharmaceuticals Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.